Navigation Links
ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance
Date:5/2/2008

ncluding its most recent annual report on Form 10-K. ev3 Inc. urges all interested parties to read this report to gain a better understanding of the many business and other risks that the company faces. Additionally, ev3 undertakes no obligation to publicly release the results of any revisions to these forward- looking statements, which may be made to reflect events or circumstances occurring after the date hereof or to reflect the occurrence of unanticipated events.

Use of Non-GAAP Financial Measures

In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), ev3 uses certain non-GAAP financial measures. In this release, ev3 uses the non-GAAP financial measures, "EBITDA, excluding charges for non-cash stock-based compensation," "peripheral vascular sales, excluding atherectomy revenues" and "adjusted earnings (loss) per share." ev3 uses non-GAAP financial measures as supplemental measures of performance and believes these measures facilitate operating performance comparisons from period to period and company to company by factoring out potential differences caused by acquisitions, non-recurring, unusual or infrequent charges not related to ev3's regular, ongoing business, variations in capital structure, tax positions, depreciation, non-cash charges and certain large and unpredictable charges. ev3 also believes that the presentation of certain non-GAAP financial measures provide useful information to investors in evaluating the company's operations, period over period. Non- GAAP measures have limitations as analytical tools, and should not be considered in isolation, or as a substitute for analysis of the company's results as reported under GAAP. When analyzing ev3's operating performance, investors should not consider ev3's EBITDA, excluding charges for non-cash stock-based compensation, ev3's peripheral vascular net sales, excluding atherectomy revenues, or ev3's adjusted earnings (loss) per share a
'/>"/>

SOURCE ev3 Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. United Therapeutics Reports First Quarter 2008 Financial Results
2. Endocare Reports 2008 First Quarter Financial Results
3. AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008
4. LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase
5. Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights
6. Neurobiological Technologies Reports Receipt of $2.0 Million Royalty Payment for Quarterly Sales of Memantine
7. Alexion Reports First Quarter 2008 Results
8. Masimo Reports First Quarter 2008 Financial Results
9. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
10. Cynosure Reports 41% Revenue Increase: 10th Consecutive Quarter of Revenue Growth
11. SuperGen Reports 2008 First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... 8 Amsterdam,Molecular Therapeutics (Euronext: AMT), a leader in ... part of the newly created Next Biotech Index of,NYSE ... our company,for this index," said Ronald Lorijn, CEO of ... companies and will help investors to track,the performance of ...
... team is proud to announce,the USDA/CVB has granted ... as well as an autogenous bacterin license utilizing ... approval of our manufacturing facility and our oral ... significant milestone for,our Company, and we look forward ...
... of Molecular Vision today,announces that discussions with Acrongenomics ... ceased. Acrongenomics has been unable to,complete on the ... of,Molecular Vision believes that the best interests of ... a conclusion. Acrongenomics remains a,significant shareholder in Molecular ...
Cached Biology Technology:Amsterdam Molecular Therapeutics Part of Next Biotech Index 2PerOs obtains USDA Establishment and Product Licenses for it's oral vaccine formulations 2
(Date:4/14/2014)... are continuing to unravel the molecular changes that underlie ... infections. , When the bacterium Yersinia pestis enters the ... 100 percent fatal if untreated. The way in which ... kills people in a matter of days has largely ... demonstrating that the presence of a protein called the ...
(Date:4/14/2014)... the decision of whether to get a dog. ... can be even more challenging. Now, a University ... in families of children with autism and found, ... reported the benefits of dog ownership included companionship, ... learn responsibility. , "Children with autism spectrum disorders ...
(Date:4/14/2014)... Think of the pressure change you feel when an elevator ... how you,d feel if that elevator carried you all the ... the blink of an eye. , That,s similar to what ... near a dam. For some, the change in pressure is ... seriously injured. , In an article in the March issue ...
Breaking Biology News(10 mins):Plague alters cell death to kill host 2Dog ownership benefits families of children with autism, MU researcher finds 2Making dams safer for fish around the world 2Making dams safer for fish around the world 3Making dams safer for fish around the world 4Making dams safer for fish around the world 5
... of Insect Molecular Biology reports the detailed analyses ... pest, the Pea Aphid. The analyses are based on ... and is a major step in enhancing our understanding of ... significant plant pests. The sequencing of the Pea ...
... have calculated the energy and economic potential of urban ... slurry for generating electricity in Spain. These residues are ... friendly and, in the case of solid urban waste, ... has economic and environmental advantages. "It gives added value ...
... the launch of the first Meteosat in 1977, 33 ... given meteorologists the tools to improve weather forecasting, with ... improving with data from operational satellites, like Meteosat Second ... basis for numerical forecasts, making use of the world,s ...
Cached Biology News:Successful genome sequencing of pea aphid is a breakthrough for ecology and agricultural research 2Successful genome sequencing of pea aphid is a breakthrough for ecology and agricultural research 3Waste could generate up to 7 percent of electricity in Spain 2Waste could generate up to 7 percent of electricity in Spain 3
...
...
... designed to rapidly and reliably amplify ... patented APA Technology. APAgene provides hassle-free, ... competitive price. All necessary ingredients are ... Kit can be used for identifying ...
Protein YIPF6 (YIP1 family member 6). [Source:Uniprot/SWISSPROT;Acc:Q96EC8] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: